Kymera Therapeutics CEO Mainolfi Executes $5.95M Stock Sale Under Pre-Arranged Plan
Kymera Therapeutics, Inc. (NASDAQ: KYMR) Chief Executive Officer Nello Mainolfi executed a significant stock sale on July 7, 2026, liquidating 50,000 shares for a total value of $5,950,000. The transaction occurred shortly after Mainolfi exercised stock options to acquire an equivalent number of shares at a substantially lower cost. This financial …